Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta issues $602 million of 4.875% convertible notes due 2030 in debt exchange

Neutral Impact 4 of 5 financing Written later

Sarepta Therapeutics exchanged $700.0 million of its 1.25% convertible notes due 2027 for $602.0 million of new 4.875% convertible notes due 2030, 5,851,693 shares of common stock and about $123.3 million in cash. The new notes were issued August 28, 2025, and the company also sold 1,106,806 shares to J. Wood Capital Advisors LLC at $18.07 per share, so shareholders face a new debt obligation alongside potential dilution from share issuance and conversion.

Key points

  • Exchanged $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due September 1, 2030, plus 5,851,693 shares and about $123.3 million in cash
  • New notes have an initial conversion price of about $60.00 per share, versus $20.58 last reported sale price on August 20, 2025
  • Interest is payable March 1 and September 1 each year, beginning March 1, 2026
  • Concurrent private placement of 1,106,806 shares to J. Wood Capital Advisors LLC at $18.07 per share

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECAug 29, 2025, 4:18 PM ET
Accession number0001193125-25-192794

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 29, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.